Business
Moderna says its vaccine candidate has ‘potential’ to confer longer-term immunity – MarketWatch
Moderna Inc. said late Thursday that its COVID-19 vaccine candidate has potential to confer longer-term immunity, and that it expects to have 20 million doses of the trial vaccine at hand in the U.S. this year. Moderna
MRNA,
+9.97%
said that according to a National Institute of Allergy and Infectious Diseases study, participants in an earlier trial stage of the vaccine candidate retained high levels of neutralizing antibodies for three months following their first vaccination (two months following…
